Abstract
Glioblastoma multiforme (GBM) is a common and aggressive malignant brain cancer with a mean survival time of approximately 15 months after initial diagnosis. Currently, the standard-of-care (SOC) treatment for this disease consists of radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ). We sought to develop an orthotopic preclinical model of GBM and to optimize a protocol for non-invasive monitoring of tumor growth, allowing for determination of the efficacy of SOC therapy using a targeted RT strategy combined with TMZ. A strong correlation (r = 0.80) was observed between contrast-enhanced (CE)-CT-based volume quantification and bioluminescent (BLI)-integrated image intensity when monitoring tumor growth, allowing for BLI imaging as a substitute for CE-CT. An optimized parallel-opposed single-angle RT beam plan delivered on average 96% of the expected RT dose (20, 30 or 60 Gy) to the tumor. Normal tissue on the ipsilateral and contralateral sides of the brain were spared 84% and 99% of the expected dose, respectively. An increase in median survival time was demonstrated for all SOC regimens compared to untreated controls (average 5.2 days,p<0.05), but treatment was not curative, suggesting the need for novel treatment options to increase therapeutic efficacy.
Original language | English |
---|---|
Article number | 1585 |
Number of pages | 12 |
Journal | Cancers |
Volume | 12 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2020 |
Keywords
- glioblastoma
- orthotopic models
- targeted radiotherapy
- bioluminescence imaging
- CT imaging
- temozolomide
- standard of care
- INFILTRATING LYMPHOCYTES
- GLIOBLASTOMA
- RADIOTHERAPY
- PROGRESSION
- HYPOXIA
- THERAPY
- CELLS
- MICE